Navrogen develops therapeutic agents that target immunosuppressive pathways affecting humoral immunity in cancer patients, utilizing antibody-drug conjugates and bispecific antibodies. The company also creates diagnostic tools to identify tumor-derived factors that inhibit humoral immune responses, enabling tailored treatment options for patients.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Tumors often suppress the humoral immune response, limiting the effectiveness of antibody-based cancer therapies. Existing treatments may be ineffective because tumor-derived factors interfere with the body's natural ability to recognize and attack cancer cells using antibodies. Identifying and overcoming these immunosuppressive mechanisms is critical for improving patient outcomes.
Solution
Navrogen develops therapeutic agents and diagnostic tools to address immunosuppressive pathways affecting humoral immunity in cancer. The company's approach involves identifying tumor-derived factors that inhibit antibody-mediated immune responses. Navrogen creates antibody-drug conjugates (ADCs) and bispecific antibodies designed to overcome these immunosuppressive effects, enhancing the efficacy of cancer treatments. Their diagnostic tools aim to identify patients whose tumors produce these inhibitory factors, enabling tailored treatment strategies that counteract tumor-induced immunosuppression.
Target Audience
Navrogen's primary customers are cancer patients, oncologists, and pharmaceutical companies focused on developing and delivering effective cancer immunotherapies.
Features
- BRITE technology to enhance antibody effector function by counteracting CA125-mediated immunosuppression.
- HIO screening platforms to identify and target humoral immunosuppressive factors.
- NAV-001: An ADC targeting mesothelin with a novel payload, designed to be refractory to CA125 inhibition.
- NAV-006: An anti-CD20 antibody.
- ICAM-1 refractory antibody-drug conjugate platform.